Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Most tumor-associated antigens represent self-proteins and as a result are poorly
immunogenic due to immune tolerance. Here we show that tolerance to carcinoembryonic …

The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with
recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation …

Background Gastrointestinal (GI) cancers are the most common human tumors encountered
worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the …

Purpose: We wanted to evaluate feasibility and safety of dendritic cell-based immunotherapy
in patients with metastatic renal cell carcinoma (RCC). Experimental Design: Patients with …

Despite significant advances in standard of care therapies, the 5-year survival rate for
metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided …

Background Immunotherapy focuses on selectively enhancing the host's immune response
against malignant disease. It has been investigated as an important treatment modality …

Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting
cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product …

Development of safe and effective cancer vaccine formulation is a primary focus in the field
of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in …